Mural Oncology (MURA) Stock Analysis

What Mural Oncology does

Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.

Key metrics

ETFs linked to MURA

Broad-market and Healthcare sector ETFs an investor holding Mural Oncology is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MURA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Mural Oncology?

Mural Oncology trades under the ticker MURA on NASDAQ.

Which exchange is MURA listed on?

MURA is listed on NASDAQ.

What sector does Mural Oncology operate in?

Mural Oncology is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MURA in a portfolio?

PortView shows MURA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.